<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22807" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatorenal Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ranasinghe</surname>
            <given-names>Indika R.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Bashar</given-names>
          </name>
          <aff>SUNY Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Khalid</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Indika Ranasinghe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bashar Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khalid Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22807.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hepatorenal syndrome (HRS) is a multiorgan condition of acute kidney injury seen in those with advanced liver disease. Patients with this condition present with signs and symptoms of liver failure as well as decreased urination as they become oliguric. This activity reviews the evaluation and management of hepatorenal syndrome and explains the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of hepatorenal syndrome.</p></list-item><list-item><p>Review the evaluation of type 1 and type 2 hepatorenal syndrome.</p></list-item><list-item><p>Summarize the medical and surgical interventions used in the management of the hepatorenal syndrome.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care and improve outcomes for patients affected by the hepatorenal syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22807&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22807">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22807.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hepatorenal&#x000a0;syndrome (HRS)&#x000a0;is a multiorgan&#x000a0;condition&#x000a0;affecting the kidneys and the liver. It is a cause of acute kidney injury that can be seen in those with acute or chronic liver disease. The first association of renal failure in cirrhosis was observed in the late 1800s. In the mid to late 1900s, further research revealed that renal failure in liver cirrhosis was functional. This was demonstrated in patients with hepatorenal syndrome with normal kidney histology in addition to the absence of proteinuria. This was further demonstrated clinically when kidneys from patients with HRS were transplanted into those with chronic kidney disease as well as the improvement of renal function in liver cirrhosis patients who underwent a liver transplant. Further research investigating renal clearance established the association of renal vasoconstriction in HRS.<xref ref-type="bibr" rid="article-22807.r1">[1]</xref></p>
      </sec>
      <sec id="article-22807.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Viral hepatitis is the&#x000a0;most common cause of liver failure, thus hepatorenal-syndrome, in developing countries. Most commonly, it is caused by Hepatitis B or, less commonly, Hepatitis C. In the developed world, the most common causes are drugs/medications; most commonly acetaminophen, chronic alcoholism or&#x000a0;any drugs that induce cytochrome p450; and non-alcoholic steatohepatitis (NASH). Less common causes of liver failure leading to&#x000a0;HRS include viruses such as&#x000a0;CMV, HHV6, and Parvovirus B19. Alternatively, vascular phenomenon like hepatic/portal vein thrombosis and metabolic causes such as nonalcoholic fatty liver disease.<xref ref-type="bibr" rid="article-22807.r2">[2]</xref></p>
      </sec>
      <sec id="article-22807.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of hepatorenal syndrome in patients with decompensated liver disease is approximately 4%. Most of these patients have portal hypertension from alcoholic hepatitis, cirrhosis, or metastatic cancers.&#x000a0;The cumulative probability of developing HRS at 1 year is 18% and at 5 years is 39% in patients with decompensated liver disease. The highest risk patients were those with hyponatremia and high plasma renin activity. One third of patients that have spontenous bacterial pertionitis can go on to develop HRS.&#x000a0;<xref ref-type="bibr" rid="article-22807.r3">[3]</xref></p>
      </sec>
      <sec id="article-22807.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cirrhosis and portal hypertension&#x000a0;can trigger&#x000a0;the neurohormonal cascade which leads to the development of HRS. This, in turn, causes&#x000a0;the&#x000a0;production and release of vasodilators and cytokines&#x000a0;like nitric oxide and&#x000a0;prostaglandins which cause splanchnic and systemic vasodilation. The systemic drop in circulating pressure triggers the carotid and aortic arch baroreceptors to activate three separate compensatory mechanisms. These include the renin-angiotensin-aldosterone system, vasopressin release, and activation of the sympathetic nervous system (SNS). The progression of the cirrhosis causes the fall in cardiac output and the fall in systemic vascular resistance in a cycle that induces further renal vasoconstriction.<xref ref-type="bibr" rid="article-22807.r3">[3]</xref>&#x000a0;This leads to further&#x000a0;renal hypoperfusion, worsened by renal vasoconstriction with the end point of renal failure.</p>
        <p>The most common precipitating factors&#x000a0;of HRS are spontaneous bacterial peritonitis, large volume paracentesis of ascites without plasma expansion and gastrointestinal bleeding.<xref ref-type="bibr" rid="article-22807.r4">[4]</xref></p>
      </sec>
      <sec id="article-22807.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Any form of sepsis&#x000a0;can cause&#x000a0;HRS in patients with liver cirrhosis, as it can&#x000a0;trigger the&#x000a0;systemic release of sepsis-related vasoactive mediators, similar to those released in portal hypertension.<xref ref-type="bibr" rid="article-22807.r5">[5]</xref></p>
      </sec>
      <sec id="article-22807.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with hepatorenal syndrome present with signs and symptoms of severe liver failure. These patients initially can present with fatigue and lethargy which can be multifactorial. This may be contributed to by loss of appetite due to increasing nausea. Over time, patients become increasingly more jaundiced, originating in the sclera and then spreading from head-to-toe.&#x000a0;The liver's synthetic function becomes affected, and patients become coagulopathic and more likely to bleed. As all this occurs, there is a very slow, gradual build-up of ascitic fluid in the peritoneum due to the intravascular loss of albumin. Confusion due to hepatic encephalopathy is likely the last and most severe stage of the liver disease as a result of the liver failing to break down toxic metabolites. Most importantly these patients notice they urinate less frequently in smaller and smaller volumes as they become oliguric. &#x000a0;<xref ref-type="bibr" rid="article-22807.r6">[6]</xref></p>
      </sec>
      <sec id="article-22807.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Hepatorenal syndrome has two types and&#x000a0;is a diagnosis of exclusion. Type 1 is characterized by rapid and progressive decline in renal function defined by&#x000a0;doubling of the serum creatinine to at least greater than 2.5 or a decrease in the creatinine clearance by half or more over a two week period. This is usually associated with a&#x000a0;urine output of less than&#x000a0;500mL/day,&#x000a0;a normal urine&#x000a0;sediment and a low urinary sodium excretion. Type 2 typically involves less severe kidney injury, and patients ordinarily present with diuretic-resistant ascites. Other apparent causes of acute kidney injury need to be excluded, including pre-renal, nephrotoxic drugs, obstructive nephropathy, and renal parenchymal disease.<xref ref-type="bibr" rid="article-22807.r7">[7]</xref></p>
      </sec>
      <sec id="article-22807.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>First and foremost, HRS involves establishing&#x000a0;euvolemia while stopping all nephrotoxic agents. The active medical treatment of HRS&#x000a0;is directed at splanchnic vasoconstriction which results in increased systemic vascular resistance and mean arterial pressure. This via counter-regulatory mechanism suppresses the renin-angiotensin-aldosterone system (RAAS)&#x000a0;and the SNS. In turn, this reduces renal vasoconstriction and improves renal blood flow. This is achieved with several different combinations of medical therapy. In Europe, a combination of terlipressin and albumin improves renal perfusion in patients with HRS Type 1 and can work in some patients with HRS Type 2.<xref ref-type="bibr" rid="article-22807.r8">[8]</xref> In North America, noradrenaline and midodrine or octreotide&#x000a0;are used for the same purpose&#x000a0;as terlipressin.<xref ref-type="bibr" rid="article-22807.r9">[9]</xref></p>
        <p>When medical management fails, surgical/interventional management&#x000a0;involves placement of a&#x000a0;transjugular intrahepatic portosystemic shunt (TIPS). This type of surgical treatment is established with the insertion of an intrahepatic stent to connect the portal vein to the hepatic vein. The shunt redirects portal blood into the systemic circulation, reducing portal pressure and increasing systemic venous return. This reduces the arterial hypoperfusion and thereby downregulates stimulation of the RAAS and SNS.<xref ref-type="bibr" rid="article-22807.r7">[7]</xref></p>
        <p>Definitive treatment for HRS is established through liver transplantation and provides the best long-term survival benefit.</p>
        <p>Other experimental techniques such as molecular adsorbent recirculating system, a modified dialysis technique aimed at removing substances causing vasodilation like nitric oxide, tumor necrosis factor, and cytokines have not been shown to improve overall survival. Renal replacement therapy has been tried in patients that do not respond to the vasoconstrictors above or are poor candidates for TIPS. However, both these therapies may be considered more appropriate as a bridge to transplant.<xref ref-type="bibr" rid="article-22807.r10">[10]</xref></p>
        <p>Patients with spontaneous bacterial peritonitis should be treated promptly and remain on long-term antibiotic therapy to prevent the development of HRS. Those with sepsis from other sources should also be treated promptly to limit the release of sepsis-related vasoactive mediators.</p>
      </sec>
      <sec id="article-22807.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute tubular necrosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Crescentic glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diffused proliferative glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Membranoproliferative glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Membranous glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Poststreptococcal glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rapidly progressive glomerulonephritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22807.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis for Type 1 HRS is poor, with an average survival of just less than 2 weeks. Type 2 HRS survival is dependent on the severity of the Child-Pugh class of liver disease, but generally more chronic and median survial was 6 to 12 months without treatment.&#x000a0;<xref ref-type="bibr" rid="article-22807.r11">[11]</xref></p>
      </sec>
      <sec id="article-22807.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Renal failure and death.<xref ref-type="bibr" rid="article-22807.r12">[12]</xref></p>
      </sec>
      <sec id="article-22807.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>New thereapeutic appoaches have demonstrated an improvement in survival for patients with HRS Type 1, but these treatment modalities were less clear in HRS Type 2. In patients with HRS Type 1, paracentesis with albumin replacement had demonstrated a median survival of slightly over 1 year. Furthermore, in patients recieving TIPS mendian suvival was shown to be extended to almost 20 months. The overall 2 year suvival in the patient reciveving paracentesis was 30-32% and in the TIPS group was 30-58%.<xref ref-type="bibr" rid="article-22807.r11">[11]</xref></p>
      </sec>
      <sec id="article-22807.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Coordination of risk assessment and management must occur between the nurses, nurse practitioner, physician, and specialists to optimize care in these patients. [Level V]</p>
      </sec>
      <sec id="article-22807.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22807&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22807">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/hepatorenal-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22807">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22807/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22807">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22807.s16">
        <title>References</title>
        <ref id="article-22807.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alabsawy</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Jalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome.</article-title>
            <source>Semin Nephrol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-30</page-range>
            <pub-id pub-id-type="pmid">30606404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivanathan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kittner</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sprinzl</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Weinmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiltink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nguyen-Tat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marquardt</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>W&#x000f6;rns</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Galle</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Schattenberg</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>[Etiology and complications of liver cirrhosis: data from a German centre].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>139</volume>
            <issue>36</issue>
            <fpage>1758</fpage>
            <page-range>1758-62</page-range>
            <pub-id pub-id-type="pmid">25157862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Hepatorenal syndrome.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-7</page-range>
            <pub-id pub-id-type="pmid">17603637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mattos</surname>
                <given-names>&#x000c2;Z</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Farias</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mattos</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Medeiros Filho</surname>
                <given-names>JEM</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dutra</surname>
                <given-names>FRD</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Schiavon</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Carvalho Filho</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fagundes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>RECOMMENDATIONS OF THE BRAZILIAN SOCIETY OF HEPATOLOGY FOR THE MANAGEMENT OF ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS.</article-title>
            <source>Arq Gastroenterol</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>314</fpage>
            <page-range>314-320</page-range>
            <pub-id pub-id-type="pmid">30540097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tonon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pilutti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morando</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sepsis-induced acute kidney injury in patients with cirrhosis.</article-title>
            <source>Hepatol Int</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-23</page-range>
            <pub-id pub-id-type="pmid">26141259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arroyo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gin&#x000e8;s</surname>
                <given-names>P</given-names>
              </name>
              <collab>EASL-CLIF Consortium CANONIC Study</collab>
            </person-group>
            <article-title>Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis.</article-title>
            <source>J Hepatol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>1 Suppl</issue>
            <fpage>S131</fpage>
            <page-range>S131-43</page-range>
            <pub-id pub-id-type="pmid">25920082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egerod Israelsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Krag</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acute kidney injury and hepatorenal syndrome in cirrhosis.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>236</fpage>
            <page-range>236-43</page-range>
            <pub-id pub-id-type="pmid">25160511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valerio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Theocharidou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion.</article-title>
            <source>World J Hepatol</source>
            <year>2016</year>
            <month>Mar</month>
            <day>08</day>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>345</fpage>
            <page-range>345-54</page-range>
            <pub-id pub-id-type="pmid">26981172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glass</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Therapeutic Options for Hepatorenal Syndrome.</article-title>
            <source>Gastroenterology</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>150</volume>
            <issue>4</issue>
            <fpage>1031</fpage>
            <page-range>1031-3</page-range>
            <pub-id pub-id-type="pmid">26922867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evolving Indications for Tips.</article-title>
            <source>Tech Vasc Interv Radiol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-41</page-range>
            <pub-id pub-id-type="pmid">26997087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Review article: prognosis of hepatorenal syndrome--has it changed with current practice?</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>20 Suppl 3</volume>
            <fpage>44</fpage>
            <page-range>44-6; discussion 47-8</page-range>
            <pub-id pub-id-type="pmid">15335400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22807.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansour</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of decompensated cirrhosis.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>18</volume>
            <issue>Suppl 2</issue>
            <fpage>s60</fpage>
            <page-range>s60-s65</page-range>
            <pub-id pub-id-type="pmid">29700095</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
